JYNT - The Joint Corp. Stock Analysis | Stock Taper
Logo
The Joint Corp.

JYNT

The Joint Corp. NASDAQ
$8.80 -4.14% (-0.38)

Market Cap $133.66 M
52w High $13.47
52w Low $7.50
P/E -880.00
Volume 36.08K
Outstanding Shares 15.19M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $13.38M $10.56M $855.01K 6.39% $0.06 $763.76K
Q2-2025 $13.27M $11.64M $93.36K 0.7% $0.01 $-714.31K
Q1-2025 $13.08M $10.78M $967.8K 7.4% $0.05 $-288.25K
Q4-2024 $-38.28M $-45.27M $-2.72M 7.09% $-0.18 $-1.19M
Q3-2024 $30.2M $30.56M $-3.17M -10.48% $-0.21 $1.86M

What's going well?

The company cut costs and swung from an operating loss to a profit. Margins improved, and net income jumped. High gross margins show the business model is strong if growth returns.

What's concerning?

Most of the profit came from one-time gains, not regular business. Revenue growth is nearly flat, so future profits may be hard to sustain without more sales.

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $30.71M $69.39M $46.66M $22.7M
Q2-2025 $29.81M $73.18M $49.92M $23.24M
Q1-2025 $21.92M $77.19M $57.26M $19.91M
Q4-2024 $25.05M $83.15M $62.48M $20.65M
Q3-2024 $20.74M $79.6M $59.12M $20.45M

What's financially strong about this company?

JYNT has a big cash cushion, very little debt, and almost half its assets are in cash or receivables. There are no risky intangibles or goodwill, and the company can easily pay all its bills.

What are the financial risks or weaknesses?

Shareholder equity dipped and retained earnings are negative, showing a history of losses. Total assets and equity both fell this quarter, which could be a concern if the trend continues.

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $290.37K $1.77M $-317.84K $-1.74M $-286.22K $1.46M
Q2-2025 $93.36K $868.65K $7.23M $0 $8.1M $363.61K
Q1-2025 $801.43K $-3.7M $-291.4K $893.18K $-3.1M $-4.03M
Q4-2024 $-2.72M $4.13M $-104.25K $-24.86K $4M $3.85M
Q3-2024 $-3.17M $3.45M $-93.94K $-6.4K $3.35M $3.2M

What's strong about this company's cash flow?

Cash from operations more than doubled this quarter, free cash flow is strong, and the company is returning cash to shareholders through buybacks. No debt and a big cash cushion provide safety.

What are the cash flow concerns?

Working capital changes are hurting cash flow, and the business saw a small overall cash decrease this quarter. If working capital swings persist, it could limit future cash growth.

Revenue by Products

Product Q4-2024Q1-2025Q2-2025Q3-2025
Advertising
Advertising
$0 $0 $0 $0
Franchise
Franchise
$0 $0 $0 $0
Product and Service Other
Product and Service Other
$0 $0 $0 $0
Royalty
Royalty
$20.00M $10.00M $10.00M $10.00M
Technology Service
Technology Service
$0 $0 $0 $0

Q3 2025 Earnings Call Summary

Read Call Summary

5-Year Trend Analysis

A comprehensive look at The Joint Corp.'s financial evolution and strategic trajectory over the past five years.

+ Strengths

The Joint’s key strengths include a distinctive, consumer-friendly model in a fragmented industry; strong brand recognition as the leading national chiropractic chain; very high gross margins that signal attractive unit economics; consistent positive operating and free cash flow; and a much-improved balance sheet with low debt and stronger liquidity. The franchise structure provides an asset-light path to scale, and the company is actively using digital tools and process innovation to enhance patient engagement and support franchisees.

! Risks

Major risks center on profitability and capital allocation. The business has shifted from strong profits to multi-year net losses, with negative retained earnings and significant write-offs of goodwill and intangibles, indicating that past growth investments have not yet paid off. Revenue has become volatile, and cost structure and overhead remain too heavy relative to current scale. The success of the franchise network is critical and could be pressured by economic downturns, competition, or operational missteps. Additionally, recent declines in cash generation and reduced capital spending suggest the company is in a more defensive, consolidating posture, increasing uncertainty around the pace and quality of future growth.

Outlook

The outlook is mixed and hinges on execution. On one hand, the company operates in a large, underpenetrated market with a differentiated model, strong gross margins, positive free cash flow, and a de-risked balance sheet — all of which provide a foundation to rebuild profitability. On the other hand, the deterioration in earnings, asset write-downs, and revenue volatility highlight that the current model and cost base are not yet fully aligned with sustainable, profitable growth. Key areas to watch include the success of the shift toward a pure-play franchisor, the trajectory of same-clinic performance and franchise openings, the ability to keep operating costs in check, and whether digital and pricing initiatives translate into more stable, profitable revenue over time.